News

The phase 1/2 BEXMAB study is investigating the combination of bexmarilimab with standard of care in patients with hematologic malignancies.

A retrospective study found no additional benefit for patients with non–small cell lung cancer who continued immunotherapy beyond 2 years.

Promising overall survival findings from cohort 1 of the THOR study evaluating erdafitinib in locally advanced or metastatic urothelial cancer have pushed the agent’s developer to submit an sNDA seeking its full approval.

Study results suggest that patients with myelodysplastic syndrome have the potential to benefit from HCT regardless of their genetic mutations.

The FDA has added to the existing approval of luspatercept-aamt for the treatment of patients with anemia and lower-risk myelodysplatic syndrome.

Combination therapies utilizing ofatumumab could improve outcomes for patients with chronic lymphocytic leukemia, according to an analysis published in the Annals of Hematology.

Chad Tang, MD, discusses ongoing challenges for the treatment of patients with oligometastatic prostate cancer.

Treatment with an investigational mitochondrial inhibitor and bevacizumab has started in a phase 1b clinical trial of patients with previously-treated metastatic colorectal cancer.

The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.

The phase 2 SWOG S1801 trial showed a 42% reduction in 2-year event-free survival for neoadjuvant-adjuvant vs adjuvant-only pembrolizumab for resectable stage IIIB-D/IV melanoma.

Ivonescimab is being investigated in phase 3 clinical trial against the combination of tislelizumab and chemotherapy.

A single-arm trial induced high event-free and overall survival with the addition of durvalumab to standard of care before radical surgery in patients with muscle-invasive urothelial carcinoma.

A coprimary end point in the phase 3 LEAP-010 study will not be met.

Based on positive phase 3 PAPILLON results, an application for a new approval for amivantamab has been filed with the FDA.

Immune checkpoint inhibitors are approved for dMMR/MSI-H gastrointestinal cancer treatment; however, approximately half of patients with dMMR/MSI-H gastrointestinal cancer exhibit primary resistance to them.

Frontline treatment with AK112, a first-in-class humanized IgG1 bispecific antibody, plus chemotherapy demonstrated promising overall responses across 3 cohorts in a phase 2 trial.

Experts believe VAL-083 has the potential to change the way oncologists treat glioblastoma in the future.

Novel agents are now under development for newly druggable targets in patients with solid tumors.

FDA notices NXC-201 for its potential offer a novel mechanism to treat patients with multiple myeloma.

Patients treated with VT1021 for recurrent glioblastoma were found to have immune markers associated with response to treatment in a phase 1/2 study.

During an Oncology Town Hall™ virtual meeting, 4 investigators in multiple myeloma addressed emerging therapies, optimal sequencing, the role of minimal residual disease to inform therapy, and the possibility of storing T cells for use in later CAR T-cell therapy.

According to Manali Bhave, MD, neratinib plus fulvestrant plus trastuzumab and should be considered as a therapeutic option with clinically meaningful benefit in patients with HER2-mutant metastatic breast cancer.

According to Marcia Brose, MD, PhD, FASCO, interim findings from the phase 3 LIBRETTO-531 trial confirms the benefit of selpercatinib in patients with advanced, RET-mutant medullary thyroid cancer.

The DeLLphi-300 trial of a bispecific T-cell engager showed favorable outcomes in patients with previously treated small cell lung cancer.

The metastasis-free survival benefit of enzalutamide, and other efficacy and safety data are now under FDA review for the potential approval of the drug for patients with non-metastatic castration-sensitive prostate cancer.

Lisocabtagene maraleucel showed activity in patients with relapsed/refractory mantle cell lymphoma, according to findings from the TRANSCEND-NHL-001 study.

In an interview with Targeted Oncology, Daniel P. Petrylak, MD, discussed findings from the TROPHY-U-01 study for patients with mUC, and what the next steps for research are.

On the heels of promising findings from the phase 3 IMerge study, the FDA has accepted the new drug application of imetelstat for transfusion-dependent anemia in patients with lower-risk MDS.

The combination of ibrutinib with chemoimmunotherapy improved the duration of response for a subset of patients with relapsed follicular lymphoma and marginal zone lymphoma.